8-K: Vera Therapeutics Expands Atacicept Development Program into Multiple Autoimmune Kidney Diseases

Vera Therapeutics announces the expansion of its atacicept development program into multiple autoimmune kidney diseases with the initiation of two new studies, ORIGIN Extend and PIONEER.

Summary

• Vera Therapeutics is expanding its atacicept development program to include a broader range of autoimmune kidney diseases.
• The company is initiating two new studies: ORIGIN Extend, which will provide long-term access to atacicept for participants in the ORIGIN trial, and PIONEER, which will evaluate atacicept in expanded IgAN populations and other autoimmune glomerular diseases.
• The PIONEER study will include adults with low kidney function, low or high proteinuria, IgAN recurrence after kidney transplant, adolescents at high risk of progression, and those with IgA vasculitis nephritis.
• The PIONEER study will also evaluate atacicept in primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS), and minimal change disease (MCD).
• The combined peak prevalence of IgAN and autoimmune-driven PMN, FSGS, and MCD in the US is estimated at approximately 230,000.
• Vera Therapeutics has approximately $384 million in cash, cash equivalents, and marketable securities as of June 30, 2024.
• The company anticipates presenting 96-week data from the Phase 2b ORIGIN study at the American Society of Nephrology Kidney Week 2024.
• The Phase 3 ORIGIN trial is on track for a readout in Q2 2025, with a potential PDUFA in 2026.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with the expansion of the atacicept program, strong financial position, and promising clinical trial results. The company is actively pursuing multiple avenues for growth and has a clear strategy for the future. The sentiment is very positive.

Positives

• The expansion of the atacicept program into multiple autoimmune kidney diseases increases the potential market for the drug.
• The ORIGIN Extend study demonstrates a commitment to providing long-term access to atacicept for trial participants.
• The PIONEER study will explore the efficacy of atacicept in a variety of patient populations, including those with low kidney function and other autoimmune glomerular diseases.
• Atacicept has shown promising results in clinical trials, including reductions in proteinuria and stabilization of eGFR.
• The company has a strong financial position with approximately $384 million in cash, cash equivalents, and marketable securities.
• Atacicept is a self-administered subcutaneous injection, which is convenient for patients.
• The company has regulatory exclusivity expected through 2038 in the US and 2037 in the EU.

Negatives

• The development of new clinical trials involves risks and uncertainties, including the potential for delays or negative results.
• The company is still in the clinical stage and has not yet received regulatory approval for atacicept.
• The success of the expanded program depends on the results of the new clinical trials.
• The company is reliant on the success of atacicept as its lead product candidate.

Risks

• The regulatory approval process for atacicept is subject to risks and uncertainties.
• Results from earlier clinical trials may not be replicated in later trials.
• Preliminary results may not be predictive of topline results.
• The company's business is subject to macroeconomic and geopolitical risks.
• There are risks associated with the company's ability to successfully commercialize atacicept.
• The company is dependent on the success of its clinical trials and regulatory approvals.

Future Outlook

Vera Therapeutics plans to initiate the ORIGIN Extend study in Q4 2024 and the PIONEER study in 2025. The company anticipates presenting 96-week data from the Phase 2b ORIGIN study at the American Society of Nephrology Kidney Week 2024. The Phase 3 ORIGIN trial is on track for a readout in Q2 2025, with a potential PDUFA in 2026. The company also plans to explore atacicept in additional rheumatologic and hematologic indications.

Management Comments

• Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics, stated that the company is committed to providing long-term access to atacicept for all ORIGIN participants.
• Dr. Fordyce also mentioned that the PIONEER study will expand the opportunity to a significantly greater number of patients with IgAN.
• Dr. Fordyce believes that B cell modulation through BAFF/APRIL dual inhibition has the potential to transform the treatment landscape for other autoimmune diseases.
• Dr. Fordyce concluded that the company has a number of significant milestones planned across its pipeline.

Industry Context

This announcement aligns with the growing focus on developing targeted therapies for autoimmune diseases, particularly in the area of nephrology. The expansion of atacicept into multiple autoimmune kidney diseases reflects a broader trend in the pharmaceutical industry to explore the potential of existing drugs in new indications. The company is positioning atacicept as a potential best-in-class treatment for IgAN and other autoimmune kidney diseases.

Comparison to Industry Standards

• Atacicept is being compared to other drugs in development for IgAN, such as Sibeprenlimab, Povetacicept and Zigakibart, based on mechanism of action, dosing, administration, and clinical trial data.
• Atacicept is a dual BAFF/APRIL inhibitor, while some competitors are only APRIL inhibitors.
• Atacicept is administered as a self-administered subcutaneous injection, which is more convenient than the intravenous or in-clinic injections of some competitors.
• Atacicept has shown a 64% reduction in proteinuria at week 36 in a randomized controlled trial, which is comparable to or better than some competitors.
• Atacicept has shown an eGFR profile consistent with the general population, which is a key goal for IgAN therapies.
• The company is targeting a potential commercial launch in 2026, which is similar to the projected timelines of some competitors.

Stakeholder Impact

• Shareholders will benefit from the potential for increased revenue and market share.
• Patients with autoimmune kidney diseases will have access to a potential new treatment option.
• Employees will have opportunities for growth and development within the company.
• The company's suppliers and partners will benefit from the increased business activity.
• Creditors will have increased confidence in the company's ability to repay its debts.

Next Steps

• Initiate the ORIGIN Extend study in Q4 2024.
• Initiate the PIONEER study in 2025.
• Present 96-week data from the Phase 2b ORIGIN study at the American Society of Nephrology Kidney Week 2024.
• Complete the Phase 3 ORIGIN trial and report top-line results in Q2 2025.
• Submit a BLA for atacicept in the second half of 2026.
• Explore atacicept in additional rheumatologic and hematologic indications.

Key Dates

Keywords

atacicept, IgAN, autoimmune kidney disease, PIONEER study, ORIGIN Extend, glomerular disease, BAFF/APRIL inhibition, proteinuria, eGFR, clinical trial, membranous nephropathy, FSGS, MCD